Opinion

Video

Prostate Cancer Treatment: Visibility Considerations With Radiation

Author(s):

Brian Mazzarella, MD,Jeffrey T. Schiff, MD, MPH

The expert panel outlines visibility considerations with the 3 rectal spacer options when treating patients with prostate cancer with radiation therapy.

Related Videos
Channing J. Paller, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Channing J. Paller, MD, answers a question during a Zoom video interview
Jaspreet S. Sandhu, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Related Content
Trial of immune therapy in mCRPC expands enrollment to VA medical center
January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke
Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
January 27th 2025

Testosterone therapy and prostate cancer: Risk-benefit and individualized treatment

Mohit Khera, MD, MBA, MPH
“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Health-related QOL is comparable among ARPI regimens for CSPC
January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke
At 25 weeks, FACT-P total score remained comparable between the arms.
EU approves Mona Lisa 2.0 robotic system for prostate cancer
January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke
The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.
© 2025 MJH Life Sciences

All rights reserved.